Nonprofit generic drug company Civica Rx is gearing up to make and sell low-cost insulin under President Biden’s Union states The comments pointed to rising insulin costs and called for a price cap of $35 a vial.
Civica plans to sell its insulin for no more than $30 a vial. By comparison, a brand-name version of insulin can cost four times that price—and even more for those without insurance. Those high prices are causing as many as 25 percent of insulin users to skip or reduce their doses, Lehi, Utah-based Civica said on Thursday. announcementciting a study published in JAMA Internal Medicine.
Civica insulin won’t be ready for another two years. The insulin manufacturing facility is still under construction and the product needs FDA approval. Civica said it would make three types of insulin, a successor to Sanofi’s Lantus, Eli Lilly’s Humalog and Novo Nordisk’s Novolog. Civica biosimilars will be manufactured in a 140,000-square-foot facility in Peterborough, Virginia. Upon completion, Civica said the site is expected to start producing insulin in early 2024 and has the capacity to produce “the bulk of insulin needed in the U.S., with additional room to increase production if necessary.” If approved by the FDA, Civica said the first Civica insulin could be available in early 2024.
In his State of the Union address, President Biden pointed to a 13-year-old Virginia boy who, along with his father, has type 1 diabetes and is dependent on daily insulin injections. Biden said a $35 price cap would make the biologic affordable while still allowing the drug company to make a profit.in a statement After the speech, the pharmaceutical industry trade group PhRMA called for a holistic legislative solution, adding that allowing “government pricing is not the answer”.
Civica said its pricing is based on the cost of developing, producing and distributing insulin. In addition to the $30 vial, insulin will also be available in pen holder form. A box of five ink cartridges costs no more than $55. The price is the same for those with insurance and those without insurance. Civica noted that current legislation proposing a price cap on insulin does not apply to uninsured people, who pay more for the drug.
Led by former Amgen executive, president and CEO Martin VanTrieste, Civica is Established in 2018 by a coalition of health organisations representing hospitalsIt initially received $30 million in funding from three charities: the Laura and John Arnold Foundation, the Peterson Health Care Center, and the Gary and Mary West Foundation. At launch, Civica focused on manufacturing 14 hospital-administered generic drugs that faced chronic shortages. In 2020, the nonprofit received $55 million in financial commitments From the Blue Cross Blue Shield Association and its 18 state insurance companies.
“We know that to truly address the insulin cost and access challenges faced by many Americans, we need a process from manufacturing to setting a transparent price that ultimately reduces the cost of the drug for people with diabetes,” Van Trieste said in Thursday’s announcement. “In this spirit, we will ensure that patients know where to buy Civica’s low-cost insulin.”
Photo: EromazeGetty Images
